Reuters logo
5 months ago
BRIEF-Catalyst Biosciences gets IND approval in South Korea for subcutaneous factor IX program
March 28, 2017 / 12:32 PM / 5 months ago

BRIEF-Catalyst Biosciences gets IND approval in South Korea for subcutaneous factor IX program

March 28 (Reuters) - Catalyst Biosciences Inc

* Catalyst Biosciences announces IND approval in South Korea for next-generation subcutaneous factor IX program

* ISU ABXIS plans to initiate phase 1/2 proof-of-concept study in individuals with severe hemophilia B in Q2 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below